SCM
BXRX

Stonepine Capital Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Stonepine Capital Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-436
Closed -$1.51M – 24
2020
Q1 		$1.51M Buy
+436
New +$4.12M 1.6% 23

Other funds holding BXRX

NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Stonepine Capital Management's BXRX Position: Q2 2020 in Review

Stonepine Capital Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2020, closing a stake of 436 shares — an estimated $1.51M sold.

Stonepine Capital Management first reported a position in BXRX in Q1 2020 and held it in 1 quarter. The position peaked at $1.51M in Q1 2020. 38 funds tracked by Wall St. Rank hold BXRX as of Q2 2020.

  • Stonepine Capital Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Stonepine Capital Management sold 436 Baudax Bio, Inc. Common Stock shares in Q2 2020, an estimated $1.51M.
  • Stonepine Capital Management first reported a position in Baudax Bio, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Stonepine Capital Management's Baudax Bio, Inc. Common Stock position peaked at $1.51M in Q1 2020.
  • 38 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2020.

Based on Stonepine Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.